Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05183230 · ClinicalTrials.gov registry record · NA
WellPATH-PREVENT: A Mobile Intervention for Middle-Aged and Older Adults Hospitalized for Suicidal Ideation or Attempt
A NA study of Depression and Suicidal Ideation, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- NA
- Development phase
- 115
- Enrollment target
- 2
- Study locations
NCT05183230: Recruiting NA study of Depression and Suicidal Ideation, sponsored by Weill Medical College of Cornell University.
NCT05183230 is a NA study of Depression and Suicidal Ideation that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 115 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05183230, a NA study of Depression and Suicidal Ideation, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- NA
- Development phase
- 115 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this project is to test whether WellPATH-PREVENT (a novel, mobile psychosocial intervention) improves a specific aspect of emotion regulation, i.e., cognitive reappraisal ability, and reduces suicide risk in middle-aged and older adults (50-90 years old) who have been discharged after a suicide-related hospitalization (i.e. for suicidal ideation or suicide attempt).
Primary Outcome
ERP is used to measure the amplitude (magnitude) of electrocortical activity (measured in μV) during an emotion regulation task.
Conditions Studied
Interventions
- BEHAVIORAL WellPATH-PREVENT
- BEHAVIORAL Optimized WellPATH-PREVENT
Study Locations (2)
New York
- New York Presbyterian Hospital/Weill Cornell Medicine - New York
- Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine - White Plains
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2022-04-22 |
| Est. Completion | 2026-09-30 |
| Phase | NA |
What NCT05183230 shows while recruiting
NCT05183230 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (85% lower).
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which WellPATH-PREVENT is the first listed.
NCT05183230 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05183230 about?
NCT05183230 is a clinical study titled "WellPATH-PREVENT: A Mobile Intervention for Middle-Aged and Older Adults Hospitalized for Suicidal Ideation or Attempt". The goal of this project is to test whether WellPATH-PREVENT (a novel, mobile psychosocial intervention) improves a specific aspect of emotion regulation, i.e., cognitive reappraisal ability, and reduces suicide risk in middle-aged and older adults (50-90 years old) who have been discharged after a ...
What is the current status of trial NCT05183230?
This trial is currently recruiting. It is a NA study. The enrollment target is 115 participants. The study started on 2022-04-22. Estimated completion is 2026-09-30.
What conditions does trial NCT05183230 study?
This clinical trial studies the following conditions: Depression, Suicidal Ideation, Suicide, Attempted.
What interventions are being tested in trial NCT05183230?
The interventions under investigation include: WellPATH-PREVENT (BEHAVIORAL), Optimized WellPATH-PREVENT (BEHAVIORAL).
Who is sponsoring clinical trial NCT05183230?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05183230 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05183230's enrollment target sits among peer trials
115 307th of 679 higher than 373 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy